REG - CelLBxHealth PLC - Q1 trading update and outlook for 2026

CellbxhealthAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260511:nRSK7622Da&default-theme=true

RNS Number : 7622D  CelLBxHealth PLC  11 May 2026

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the EU Market Abuse
Regulation (596/2014) as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018, as amended. Upon the publication of
this announcement via a regulatory information service, this information is
considered to be in the public domain.

 

CelLBxHealth plc

 ("CelLBxHealth" or "the Company")

 

Q1 trading update and outlook for 2026

 

Guildford, UK and Plymouth Meeting, U.S. - 11 May 2026 - CelLBxHealth plc
(AIM: CLBX), a CTC intelligence company specialising in innovative circulating
tumor cell (CTC) solutions for use in research, drug development and clinical
oncology, provides a trading update for Q1 2026 and outlook for FY 2026 (year
ending 31 December 2026).

 

Trading in first quarter of the year, reflected the Company's initial focus on
the necessary organisational restructuring required under the revised business
strategy. Management have concentrated efforts on securing significant
cost-saving measures, whilst ensuring the business is right-sized to deliver
on sensible commercial milestones and to execute on key leads within the sales
pipeline. Following last year's 60% reduction in headcount the business has
been further reduced from 44 full-time employees (FTEs) to 39 FTEs in the
first quarter. These actions, combined with additional forecast cost saving
efforts, have resulted in reducing annual cash operating costs in 2026 by more
than £6.6 million. Further identified costs to be rationalised in Q2 2026 are
expected to deliver savings of an additional £0.1 million. Cash at 31 March
2026 was £4.3 million, in-line with expectations and reflecting one-off costs
associated with the restructuring of the business.

 

Outlook for 2026

 

Whilst making the much-needed cost reductions, as detailed above, there is
also an acute focus on driving commercial progress and revenue growth;
accordingly the Company has appointed a new head of sales in the US. The Board
remains confident in delivering significant growth in 2026 and the qualified
sales pipeline continues to build. It remains early in the Company's
turnaround, but based on contracted revenues and sales opportunities expected
to convert shortly, the Board is confident in delivering revenues for FY 2026
of at least £2.1 million, a 50% increase on FY 2025. There are a number of
other opportunities in the sales pipeline that could convert during the
remainder of the financial year, which would allow the Company to increase
revenue guidance for the full year.

 

The Company is in advanced discussions with one of the largest private US
healthcare providers to use CelLBxHealth's Parsortix® platform in two
clinical studies and is also in the final stages of concluding a Master
Services Agreement with a top ten global pharmaceutical company for the use of
the Parsortix® platform to potentially support drug discovery and
development. Further updates will be provided to shareholders in due course.
The Company has also completed a sub-lease agreement for a part of its US
facility.

 

The Board remain confident of delivering significant growth in 2026 and beyond
and will provide a further update alongside its final results for FY 2025
which will be announced in the latter part of June.

 

The Company has also recently update its corporate website, which can be
viewed here: https://cellbxhealth.com/ (https://cellbxhealth.com/)

 

For further information:

 

 CelLBxHealth plc                                investor@cellbxhealth.com (mailto:investor@cellbxhealth.com)

 Peter Collins, Chief Executive Officer          via Walbrook PR

 Jan Groen, Executive Chairman

 Cavendish (NOMAD and Broker)                    +44 (0)20 7220 0500

 Geoff Nash / Isaac Hooper (Corporate Finance)

 Sunila de Silva (Corporate Broking)

 Nigel Birks (Life Science Specialist Sales)

 Walbrook PR (Investor and Media Relations)      Tel: +44 (0)20 7933 8780 or CelLBx@walbrookpr.com

                                               (mailto:CelLBx@walbrookpr.com)
 Paul McManus / Alice Woodings

                                                 Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

About CelLBxHealth plc

CelLBxHealth plc is a CTC intelligence company specialising in innovative
circulating tumor cell (CTC) solutions for use in research, drug development
and clinical oncology. Its patent-protected Parsortix® Platform harvests CTCs
from blood and can be integrated with existing laboratory instruments for
comprehensive downstream analysis - including whole-cell imaging, proteomic
profiling and full genomic workflows.

 

Commercial focus span three revenue streams - Product Sales of the Parsortix
platform and consumables through CRO and clinical lab partnerships, Laboratory
Services including clinical trial support and assay development delivered from
a GCLP-compliant UK facility, and Lab Developed Tests (LDTs), pursued through
a combination of strategic partnerships and in-house development.

 

For more information, visit https://cellbxhealth.com/
(https://cellbxhealth.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFFFILETIILIR



            Copyright 2019 Regulatory News Service, all rights reserved